COMMUNIQUÉS West-GlobeNewswire
-
Declaration de NANOBIOTIX concernant une recente rumeur mediatique
25/03/2026 -
SafeSpace Global to Attend ISC West 2026 to Strengthen Industry Relationships and Expand Strategic Pipeline
25/03/2026 -
Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis
25/03/2026 -
Flyte Hops: Vision Jet Platform Seeks to Redefine Private Aviation
25/03/2026 -
SRx Health Solutions Hedges Decentralized Finance (DeFi) Portfolio with Investment in Gold and Reduces its Emerging Market Hedge
25/03/2026 -
TOMI Environmental Solutions’ Binary Ionization Technology Approved in the Netherlands
25/03/2026 -
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
25/03/2026 -
Jushi Holdings Inc. Announces First Settlement in Ongoing Hemp-Derived THC Litigation
25/03/2026 -
NANOBIOTIX Statement Regarding Recent Media Speculation
25/03/2026 -
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
25/03/2026 -
SEMCAP Launches SEMCAP Beauty & Wellness to Capitalize on Opportunities in Burgeoning Longevity and Consumer Wellbeing Space
25/03/2026 -
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
25/03/2026 -
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
25/03/2026 -
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
25/03/2026 -
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
25/03/2026 -
Philips launches IntraSight Plus to simplify coronary interventions and advance precision care
25/03/2026 -
Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approval
25/03/2026 -
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
25/03/2026 -
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
25/03/2026
Pages